MYC and acute myeloid leukemia: The G4 stabilizer APTO‐253 showed the ability to repress MYC in acute myeloid leukemia (AML) cells [134] and was tested in a phase I clinical trial in patients with relapsed AML (https://ClinicalTrials.gov/show/NCT02267863).